Revista de informes de casos clínicos

Successful Treatment of COVID-19 Pneumonia using Hydroxychloroquine, Azithromycin, and Tocilizumab

Abstract

Drew G. Jones, Rebeccah Collins and Kevin Malloy

As of April 15, 2020 there were 1,914,916 confirmed cases of coronavirus disease 2019 (COVID-19) responsible for 123,010 deaths throughout the world. Facing mortality rates near 5%, the global medical community is racing to develop effective therapies against this viral pandemic. Current management of COVID-19 is largely supportive, with interventions directed at prevention and treatment of severe pulmonary complications including Acute Respiratory Distress Syndrome (ARDS), the leading cause of mortality in the disease. A small epidemiologic study of an early cohort of patients with laboratory-confirmed disease suggested a correlation between cytokine-driven inflammation and disease severity with progression to ARDS.3 Here we present the case of an acutely ill patient diagnosed with COVID-19 pneumonia who was successfully treated with a supportive care regimen which included tocilizumab.